Business Description
Cyclacel Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US23254L4059
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 91.3 | |||||
Equity-to-Asset | 0.07 | |||||
Debt-to-Equity | 0.06 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -77.55 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 12 | |||||
3-Year EPS without NRI Growth Rate | 20 | |||||
3-Year FCF Growth Rate | 17 | |||||
3-Year Book Growth Rate | -80.7 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 43.97 | |||||
9-Day RSI | 39.66 | |||||
14-Day RSI | 38.63 | |||||
6-1 Month Momentum % | -79.19 | |||||
12-1 Month Momentum % | -79.9 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.91 | |||||
Quick Ratio | 0.91 | |||||
Cash Ratio | 0.41 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -36.5 | |||||
Shareholder Yield % | 1.15 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -6060.24 | |||||
Net Margin % | -5370.24 | |||||
FCF Margin % | -3872.35 | |||||
ROE % | -227.33 | |||||
ROA % | -128.37 | |||||
ROIC % | -862.97 | |||||
ROC (Joel Greenblatt) % | -17700.28 | |||||
ROCE % | -254.78 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 3.5 | |||||
PB Ratio | 3.05 | |||||
Price-to-Tangible-Book | 3.1 | |||||
EV-to-EBIT | 0.04 | |||||
EV-to-EBITDA | 0.04 | |||||
EV-to-Revenue | -2.46 | |||||
EV-to-FCF | 0.06 | |||||
Earnings Yield (Greenblatt) % | 2500 | |||||
FCF Yield % | -698.66 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Cyclacel Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 0.387 | ||
EPS (TTM) (€) | -24.833 | ||
Beta | -1.14 | ||
Volatility % | 99.5 | ||
14-Day RSI | 38.63 | ||
14-Day ATR (€) | 0.090433 | ||
20-Day SMA (€) | 1.7455 | ||
12-1 Month Momentum % | -79.9 | ||
52-Week Range (€) | 1.41 - 10.364999 | ||
Shares Outstanding (Mil) | 1.32 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Cyclacel Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Cyclacel Pharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Cyclacel Pharmaceuticals Inc Frequently Asked Questions
What is Cyclacel Pharmaceuticals Inc(STU:UXI)'s stock price today?
When is next earnings date of Cyclacel Pharmaceuticals Inc(STU:UXI)?
Does Cyclacel Pharmaceuticals Inc(STU:UXI) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |